Abstract
72
In this study, we successfully derived human induced pluripotent stem cells (hiPSCs) 73 from a patient with CPT II deficiency, differentiated them into a mature myocyte lineage 74 within 2 weeks in a highly efficient and reproducible manner, and recapitulated some of the 75 disease phenotypes associated with CPT II deficiency. We discuss the opportunities to use 76 iPSC technology for modeling defects in FAO and for evaluating therapeutic regimens for 77 CPT II deficiency. The subject of the current study was a 24-year-old Japanese man whose genetic and 82 clinical presentation has already been described [10] 
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Heat stimulation: Differentiated myocytes on culture day 9 were subjected to heat stress 176 at 38°C on a hot plate. 
225
suggest that disease-specific iPSCs can be generated from the skin fibroblasts of a CPT 226 II-deficient patient. 
311
In conclusion, we successfully derived disease-specific iPSCs from a patient with CPT 312 II deficiency and differentiated them into myocytes. Our results suggest that cellular models 313 using patient-derived iPSCs will be of significant benefit for research groups studying CPT II 314 deficiency-related diseases, and that these iPSC disease models may be a valuable resource 315 for testing novel therapeutic strategies for these disorders. 
